National Cancer Institute; Notice of Closed Meetings, 21827 [2017-09412]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 89 / Wednesday, May 10, 2017 / Notices
The second day of the Biomedical
Library and Informatics Review
Committee meeting, June 16, 2017, will
now be held from 8:00 a.m. to 6:00 p.m.
instead of 8:00 a.m. to 2:00 p.m. The
meeting is closed to the public.
Dated: May 4, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09414 Filed 5–9–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
jstallworth on DSK7TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Coordinating Center for Population-based
Research to Optimize the Screening Process.
Date: June 13, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W112, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jennifer C. Schiltz, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Bethesda, MD
20892–9750, 240–276–5864, jennifer.schiltz@
nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Biological
Comparisons in Patient-Derived Models of
Cancer.
Date: June 14, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W236, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Robert Coyne, Ph.D.,
Scientific Review Officer, Special Review
VerDate Sep<11>2014
15:21 May 09, 2017
Jkt 241001
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W236, Bethesda, MD
20892–9750, 240–276–5120, coynes@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Partnerships in Cancer Research (P20) and
Cancer Health Equity (U54).
Date: June 20–21, 2017.
Time: 7:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Clifford Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Bethesda, MD 20892–9750, 240–276–6343,
schweinfestcw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: May 4, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09412 Filed 5–9–17; 8:45 am]
BILLING CODE 4140–01–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–945]
Certain Network Devices, Related
Software and Components Thereof (II);
Commission Final Determination of
Violation of Section 337; Termination
of Investigation; Issuance of Limited
Exclusion Order and Cease and Desist
Order
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has found a violation of
section 337 of the Tariff Act of 1930, as
amended, in the above-captioned
investigation. The Commission has
determined to issue a limited exclusion
order. The investigation is terminated.
FOR FURTHER INFORMATION CONTACT:
Megan M. Valentine, Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street SW.,
Washington, DC 20436, telephone (202)
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
21827
708–2301. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on January 27, 2015, based on a
Complaint filed by Cisco Systems, Inc.
of San Jose, California (‘‘Cisco’’). 80 FR
4313–14 (Jan. 27, 2015). The Complaint
alleges violations of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, in the sale for importation,
importation, and sale within the United
States after importation of certain
network devices, related software and
components thereof by reason of
infringement of certain claims of U.S.
Patent Nos. 7,023,853; 6,377,577;
7,460,492; 7,061,875; 7,224,668; and
8,051,211. The Complaint further
alleges the existence of a domestic
industry. The Commission’s Notice of
Investigation named Arista Networks,
Inc. of Santa Clara, California (‘‘Arista’’)
as respondent. The Office of Unfair
Import Investigations (‘‘OUII’’) was also
named as a party to the investigation.
The Commission previously terminated
the investigation in part as to certain
claims of the asserted patents. Order No.
38 (Oct. 27, 2015), unreviewed Notice
(Nov. 18, 2015); Order No. 47 (Nov. 9,
2015), unreviewed Notice (Dec. 1, 2015).
On December 9, 2016, the ALJ issued
her Final ID, finding a violation of
section 337 with respect to claims 1, 7,
9, 10, and 15 of the ’577 patent; and
claims 1, 2, 4, 5, 7, 8, 10, 13, 18, 56, and
64 of the ’668 patent. The ALJ found no
violation of section 337 with respect to
claim 2 of the ’577 patent; claims 46 and
63 of the ’853 patent; claims 1, 3, and
4 of the ’492 patent; claims 1–4, and 10
of the ’875 patent; and claims 2, 6, 13,
and 17 of the ’211 patent.
In particular, the Final ID finds that
Cisco has shown by a preponderance of
the evidence that the accused products
infringe asserted claims 1, 7, 9, 10, and
15 of the ’577 patent; and asserted
claims 1, 2, 4, 5, 7, 8, 10, 13, 18, 56, and
E:\FR\FM\10MYN1.SGM
10MYN1
]]>Agencies
[Federal Register Volume 82, Number 89 (Wednesday, May 10, 2017)]
[Notices]
[Page 21827]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09412]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Coordinating Center for Population-based Research to Optimize
the Screening Process.
Date: June 13, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W112, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Jennifer C. Schiltz, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W264, Bethesda, MD 20892-9750, 240-276-5864,
jennifer.schiltz@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Biological Comparisons in Patient-Derived Models of Cancer.
Date: June 14, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Room 7W236, Rockville, MD 20850 (Telephone Conference
Call).
Contact Person: Robert Coyne, Ph.D., Scientific Review Officer,
Special Review Branch, Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W236,
Bethesda, MD 20892-9750, 240-276-5120, coynes@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel; Partnerships in Cancer Research (P20) and Cancer Health
Equity (U54).
Date: June 20-21, 2017.
Time: 7:30 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Clifford Schweinfest, Ph.D., Scientific Review
Officer, Special Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical Center Drive, Room
7W108, Bethesda, MD 20892-9750, 240-276-6343,
schweinfestcw@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: May 4, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-09412 Filed 5-9-17; 8:45 am]
BILLING CODE 4140-01-P
